Download PDF
Thromb Haemost 2001; 85(02): 193-194
DOI: 10.1055/s-0037-1615674
Commentary
Schattauer GmbH

MHC Class II and III Polymorphisms and the Antiphospholipid Syndrome

Monica Galli
1   Divisione di Ematologia, Ospedali Riuniti, Bergamo, Italy
› Author Affiliations
Further Information

Publication History

Publication Date:
08 December 2017 (online)

Also available at
    Permissions and Reprints

 

 

  • References

  • 1 Godfrey T, D’Cruz D. Antiphospholipid syndrome: general features. In: Khamashta MA. (ed). Hughes’ syndrome. London: Springer; 2000: 8-19.
    Google Scholar
  • 2 Asherson RA. A “primary” antiphospholipid syndrome?. J Rheumatol 1988; 15: 1742-6.
    PubMedGoogle Scholar
  • 3 Alarcon-Segovia D, Deleze M, Oria CV, Sanchez-Guerrero J, Gomez-Pacheco L, Cabiedes J, Fernandez L, Ponce de Leon S. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. Medicine 1989; 68: 353-65.
    CrossrefPubMedGoogle Scholar
  • 4 Wilson WA, Gharavi AE. Genetic risk factors for aPL syndrome. Lupus 1996; 5: 398-403.
    CrossrefPubMedGoogle Scholar
  • 5 Galli M, Bevers EM, Barbui T. Immunologic properties and anticoagulant activities of antiphospholipid antibodies. In: Levine SR, Brey RL. (eds). Clinical Approach to Antiphospholipid Antibodies. Boston: Butterworth Heinemann; 2000: 19-41.
    Google Scholar
  • 6 Hartung K, Coldewey R, Corvetta A, Deicher H, Kalden JR, Krapf F, Lang B, Lakomek Hj, Leidvogel B, Peter HH. MHC gene products and anti-cardiolipin antibodies in systemic lupus erythematosus. Results of a multi-center study. Autoimmunity 1992; 13: 95-9.
    CrossrefPubMedGoogle Scholar
  • 7 Asherson RA, Doherty DG, Vergani D, Khamashta MA, Hughes GRV. Major histocompatibility complex associations with primary antiphospholipid syndrome. Arthritis Rheum 1992; 35: 124-5.
    CrossrefPubMedGoogle Scholar
  • 8 Arnett FC, Olsen ML, Anderson KL, Reveille JD. Molecular analysis of major histocompatibility complex alleles associated with the lupus anticoagulant. J Clin Invest 1991; 87: 1490-5.
    CrossrefPubMedGoogle Scholar
  • 9 Arnett FC, Thiagarajan P, Ahn C, Reveille JD. Association of anti-β2-glycoprotein I autoantibodies with HLA class II alleles in three ethnic groups. Arthritis Rheum 1999; 42: 268-74.
    CrossrefPubMedGoogle Scholar
  • 10 Wilson WA, Scopelitis E, Machalski JP, Pierangeli SS, Silvera LH, Elston RC, Harris EN. Familial anticardiolipin antibodies and C4 deficiency geno-types that coexist with MHC DQB1 risk factors. J Rheumatol 1995; 22: 227-35.
    PubMedGoogle Scholar
  • 11 Arvieux J, Roussel B, Ponard D, Colomb MG. IgG2 subclass restriction of anti-β2-glycoprotein I antibodies in autoimmune patients. Clin Exp Immunol 1994; 95: 310-5.
    PubMedGoogle Scholar
  • 12 Galli M, Comfurius P, Barbui T, Zwaal RFA, Bevers EM. Anticoagulant activity of β2-glycoprotein I is potentiated by a distinct subgroup of anti-cardiolipin antibodies. Thromb Haemost 1992; 68: 297-300.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Bertolaccini ML, Atsumi T, Caliz AR, Amengual O, Khamashta MA, Hughes GR, Koike T. Association of antiphosphatidylserine/prothrombin autoantibodies with HLA class II genes. Arthritis Rheum 2000; 43: 683-8.
    CrossrefPubMedGoogle Scholar
  • 14 Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, Van der Vanden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.
    CrossrefPubMedGoogle Scholar
  • 15 Galli M, Finazzi G, Duca F, Norbis F, Moia M. The G1691A mutation of factor V, but not the G20210A mutation of factor II or the C677T mutation of methylenetetrahydrofolate reductase genes, is associated with venous thrombosis in patients with lupus anticoagulants. Br J Haematol 2000; 108: 865-70.
    CrossrefPubMedGoogle Scholar
  • 16 Ruiz-Arguelles GJ, Ruiz-Arguelles A, Alarcon-Segovia D, Drenkard C, Villa A, Cabiedes J, Presno-Bernal M, Deleze M, Ortiz-Lopez R, Vazquez-Prado J. Natural anticoagulants in systemic lupus erythematosus. Deficiency of protein S bound to C4bp associates with recent history of venous thrombosis, antiphospholipid antibodies, and the antiphospholipid syndrome. J Rheumatol 1991; 18: 552-8.
    PubMedGoogle Scholar
  • 17 Comp P, Esmon C. Recurrent venous thromboembolism in patients with a partial deficiency of protein S. N Engl J Med 1984; 311: 1525-7.
    CrossrefPubMedGoogle Scholar
  • 18 Hessing M. The interaction between complement component C4b-binding protein and the vitamin K-dependent protein S forms a link between blood coagulation and the complement system. Biochem J 1991; 277: 581-92.
    CrossrefPubMedGoogle Scholar
  • 19 Bertolaccini ML, Atsumi T, Lanchbury JS, Caliz AR, Katsumata K, Vaughan RW, Kondeatis E, Khamashta MA, Koike T, Hughes GRV. Plasma tumor necrosis factor alpha levels and the -238*A promoter polymorphism in patients with antiphospholipid syndrome. Thromb Haemost 2001; 85: 198-203.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 20 Vassalli P. The pathophysiology of tumor necrosis factor. Ann Rev Immunol 1992; 10: 411-52.
    CrossrefPubMedGoogle Scholar
  • 21 Rudwaleit M, Tikly M, Khamashta M, Gibson K, Klinke J, Hughes G, Wordsworth P. Interethnic differences in the association of tumor necrosis factor promoter polymorphisms with systemic lupus erythematosus. J Rheumatol 1996; 23: 1725-8.
    PubMedGoogle Scholar